Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader…
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology…
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
March 03, 2025 06:00 ET | Source: Can-Fite BioPharma Ltd. Unlike chemotherapy…
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month…
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc.…
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
February 23, 2025 12:07 ET | Source: IO Biotech • Findings support…
Olema Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 19, 2025 16:30 ET | Source: Olema Oncology SAN FRANCISCO, Feb.…
FDA Approves Samsung Bioepis OSPOMYV, XBRYK (denosumab-dssb), a Biosimilar to Prolia and Xgeva
OSPOMYV™ and XBRYK™ approved by the U.S. Food and Drug Administration (FDA)…
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily…
Incyclix Bio Announces Publication in Nature Communications Highlighting Biomarkers of Response to CDK2 Inhibition
February 13, 2025 08:00 ET | Source: Incyclix Bio RESEARCH TRIANGLE PARK,…